“The Tesla and SpaceX CEO sent an email to employees at both companies on Tuesday saying everyone must spend 40 hours per week in the office. ‘If you don’t show up, we will assume you have resigned. The more senior…
REGULATORY
12 New Probable Cases of Mysterious Pediatric Hepatitis Detected in Japan
Twelve new “probable” cases of pediatric acute hepatitis of unknown etiology were found in Japan, bringing the total number of such detections to 24, the Japanese health ministry said on May 20. According to the WHO’s tentative definition, a probable…
To read the full story
Related Article
- Japan Finds 4 More Probable Cases of Acute Hepatitis in Children
June 27, 2022
- Japan Detects 11 More Probable Cases of Mysterious Hepatitis in Children
June 20, 2022
- Japan Confirms 11 More Probable Cases of Acute Hepatitis in Children
June 13, 2022
- Japan Reports 5 More Probable Cases of Acute Hepatitis in Children
June 6, 2022
- 7 New Probable Cases of Pediatric Hepatitis Reported in Japan
May 31, 2022
- 5 New Probable Cases of Acute Pediatric Hepatitis Found in Japan
May 16, 2022
- Probable Cases of Mysterious Pediatric Hepatitis Now Increased to 7 in Japan
May 9, 2022
REGULATORY
- Safety of Emergency Approval Products to Be Monitored with RMP: Official
June 27, 2022
- MHLW Panel OKs 56 More Health Damage Claims for COVID-19 Vaccines
June 27, 2022
- Japan Finds 4 More Probable Cases of Acute Hepatitis in Children
June 27, 2022
- PMDA Reviewing Safety Risks for Imfinzi and Bavencio
June 27, 2022
- Health Minister Visits Takeda Manufacturing Site for Novavax Jab, Stresses Need to Handle Diverse Modalities in Japan
June 24, 2022
Pharma companies have seen Japan’s new “zero” premium coefficient rule extensively applied to medicines with low cost disclosure ratios since its introduction under the drug pricing reform this April. Of new drugs listed in the past two months, all six…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…